FDA’s Patient-Focused Meetings: Round One Selections Include Diseases Broad And Rare
Executive Summary
Breast and lung cancer, female sexual dysfunction and hemophilia are among 16 diseases that FDA will discuss with patients to get their perspective for drug development; additional diseases will be chosen in a future round.